Open AccessHPV 9G DNA Chip: 100% Clinical Sensitivity and Specificity
Author(s) -
Hee-Jung An,
Ki-Bong Song,
Satish Balasaheb Nimse,
Jung-Hoon Kim,
Van-Thuan Nguyen,
Van-Thao Ta,
Danishmalik Rafiq Sayyed,
Taisun Kim
Publication year - 2012
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.06217-11
Subject(s) - genotyping , primer (cosmetics) , genotype , dna , biology , dna microarray , virology , microbiology and biotechnology , genetics , gene , chemistry , gene expression , organic chemistry
We describe a novel HPV 9G DNA chip test for the accurate and reliable genotyping of human papillomavirus (HPV). The HPV 9G DNA chip test established its efficiency in terms of a signal-to-background ratio (SBR) of 200, which is 50 times superior to commercial HPV DNA chips, and 100% target-specific hybridization at 25°C. We compared the genotyping results for the 439 clinical samples by the HPV 9G DNA chip test with the sequencing results for the MY11/GP6+ (M2) primer set-mediated PCR products. The discrimination of HPV genotypes in the 151 HPV-positive clinical samples by the HPV 9G DNA chip test were 100% identical with the sequencing analysis. The clinical sensitivities of HPV genotyping by the HPV 9G DNA chip test and a commercial HPV DNA chip test were 100% and 88%, respectively. However, the clinical specificities of HPV genotyping by the HPV 9G DNA chip test and the commercial HPV DNA chip test were 100% and 94%, respectively. The 100% clinical sensitivity and specificity of the HPV 9G DNA chip test make it a promising diagnostic tool for HPV genotyping.